Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 25.05.2026 3 Ann Surg Oncol 1 ANZ J Surg 1 Asian Pac J Cancer Prev 1 Bioengineered 1 BJUI Compass 1 Bladder Cancer 1 Cancer Biomark 1 Cancer Cytopathol 1 Cell Death Differ 2 Cell Death Dis 1 Cell Oncol (Dordr) 1 Chin Clin Oncol 1 Clin Case Rep 2 Clin Genitourin Cancer 1 Clin Nutr 2 Clin Transl Oncol 1 Curr Pharm Des 2 Discov Oncol 1 Discoveries (Craiova) 1 Drug Dev Res 5 Eur Urol 2 Expert Rev Anticancer Ther 1 Expert Rev Pharmacoecon Outcomes Res 1 FASEB J 1 Funct Integr Genomics 1 Future Oncol 1 J Biotechnol 1 J Cancer Res Clin Oncol 1 J Clin Oncol 1 J Formos Med Assoc 1 J Immunother Cancer 1 J Natl Compr Canc Netw 1 J Transl Med 2 J Urol 1 JCI Insight 1 JMIR AI 1 Jpn J Radiol 1 Medicine (Baltimore) 1 Mol Med 1 NPJ Precis Oncol 1 Nutr Cancer 1 Occup Environ Med 1 Oncol Lett 1 Oncol Ther 2 Pathol Res Pract 9 Transl Androl Urol 1 Urol Oncol 2 World J Surg Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
   Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.
   Ann Surg Oncol. 2026 May 17. doi: 10.1245/s10434-026-19790.
   PubMed         Abstract available
   
   
2. DATA S, Trivedi S, Singh Y, Kumar U, et al
   HMGB1, An Autophagy-Associated Gene, as a Novel Non-Invasive Diagnostic Biomarker: Clinicopathologic Correlation in Urinary Bladder Carcinoma Patients.
   Ann Surg Oncol. 2026;33:5470-5477.
   PubMed         Abstract available
   
   
3. POLVERINO F, Catanzaro C, Nicolazzini M, Petix M, et al
   Alcohol Use Disorder versus Adverse In-Hospital Outcomes after Radical Cystectomy and Ileal Conduit Urinary Diversion.
   Ann Surg Oncol. 2026;33:5847-5853.
   PubMed         Abstract available
   
   

   
   ANZ J Surg

4. BUCKBY A, Gholami M, Hong M, O'Callaghan M, et al
   Androgen Receptor Expression in Urothelial Bladder Cancer-A Systematic Review and Meta-Analysis.
   ANZ J Surg. 2026 May 21. doi: 10.1111/ans.70752.
   PubMed         Abstract available
   
   

   
   Asian Pac J Cancer Prev

5. ALUBAIDY HA, Al-Bdeery AH, Abdul-Adel E, Juda SA, et al
   Role of Cyanidin 3-glucoside Extract in the Induction of Cytotoxicity and Apoptosis in a Rat Bladder Cancer Cell Line.
   Asian Pac J Cancer Prev. 2026;27:1795-1804.
   PubMed         Abstract available
   
   

   
   Bioengineered

6. 
   Statement of Retraction: Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-beta signalling pathway.
   Bioengineered. 2026;17:2667619.
   PubMed        
   
   

   
   BJUI Compass

7. HANNA J, Fu MZ, Inan B, Guevara D, et al
   Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
   BJUI Compass. 2026;7:e70215.
   PubMed         Abstract available
   
   

   
   Bladder Cancer

8. COLE A, Shoskes DA, Henderson RJ
   Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.
   Bladder Cancer. 2026;12:23523735261447111.
   PubMed         Abstract available
   
   

   
   Cancer Biomark

9. LI H, Zhu D
   Development and verification of cell cycle-related gene markers for prognosis in bladder cancer.
   Cancer Biomark. 2026;43:18758592261449024.
   PubMed         Abstract available
   
   

   
   Cancer Cytopathol

10. LAJARA S, Cuda J, Geisler DL, Staniszewski C, et al
    Enhancing urothelial carcinoma diagnosis with artificial intelligence-integrated urine cytology: Biopsy-validated accuracy and efficiency gain.
    Cancer Cytopathol. 2026;134:e70110.
    PubMed         Abstract available
    
    

    
    Cell Death Differ

11. ZHAO JG, Chen ZY, Pan HQ, Jin Y, et al
    ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression.
    Cell Death Differ. 2026 May 21. doi: 10.1038/s41418-026-01764.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

12. KAO WH, Liao LZ, Chen YA, Lo UG, et al
    Correction: SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.
    Cell Death Dis. 2026;17:473.
    PubMed        
    
    
13. CHEN R, Su Y, Chen J, Zhu S, et al
    TRIM28-mediated SUMOylation of SREBF1 drives PD?L1 N?glycosylation and immune evasion in bladder cancer.
    Cell Death Dis. 2026 May 18. doi: 10.1038/s41419-026-08798.
    PubMed         Abstract available
    
    

    
    Cell Oncol (Dordr)

14. WANG B, Zheng X, Hua Q, Zou F, et al
    NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation.
    Cell Oncol (Dordr). 2026 May 18. doi: 10.1007/s13402-026-01219.
    PubMed         Abstract available
    
    

    
    Chin Clin Oncol

15. AKAI T, Yamamichi G, Miyamoto H
    Role of androgen receptor signaling in chemoresistance in urothelial cancer: a narrative review.
    Chin Clin Oncol. 2026;15:39.
    PubMed         Abstract available
    
    

    
    Clin Case Rep

16. JUAN L, Weiping C
    Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report.
    Clin Case Rep. 2026;14:e72641.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

17. NADELMANN J, Baca AL, Labagnara K, Dave P, et al
    Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population.
    Clin Genitourin Cancer. 2026;24:102564.
    PubMed         Abstract available
    
    
18. SUARTZ CV, de Lima RD, Setoue DND, Brito PHS, et al
    Role of Neoadjuvant Therapy in Histological Variant Urothelial Carcinoma.
    Clin Genitourin Cancer. 2026;24:102528.
    PubMed         Abstract available
    
    

    
    Clin Nutr

19. DAI YN, Tura B, Yu EY, Zeegers MP, et al
    Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programme.
    Clin Nutr. 2026;62:106679.
    PubMed         Abstract available
    
    

    
    Clin Transl Oncol

20. BOROWCZAK J, Podemska E, Drobnik M, Gawrych A, et al
    HSP90beta as a potential prognostic biomarker in urothelial carcinoma: insights from NF-kappaB, IL-8, and heat-shock protein expression.
    Clin Transl Oncol. 2026;28:2335-2344.
    PubMed         Abstract available
    
    
21. SAEED DF, Amer NN, Ismail A, Abdelbary A, et al
    Integrative in silico and clinical validation of urinary lncRNAs (SNHG7 & LINC00675) and beta-catenin mRNA as molecular markers for early bladder cancer detection.
    Clin Transl Oncol. 2026 May 21. doi: 10.1007/s12094-026-04392.
    PubMed         Abstract available
    
    

    
    Curr Pharm Des

22. LI J, Zhang S, Yu S, Shen Y, et al
    Mechanistic Insights into Xihuang Wan against Bladder Cancer via PI3K/ AKT/BCL2-Mediated Apoptosis Inhibition: Integrated Network Pharmacology, Molecular Docking, Molecular Dynamics Simulations and Experimental Validation.
    Curr Pharm Des. 2026 May 13. doi: 10.2174/0113816128435835260116205839.
    PubMed         Abstract available
    
    

    
    Discov Oncol

23. ZHAO X, Qin R, Shen C, Hu D, et al
    Integrating machine learning and structural analysis to decipher benzo[a]pyrene-induced bladder cancer networks.
    Discov Oncol. 2026 May 21. doi: 10.1007/s12672-026-05207.
    PubMed         Abstract available
    
    
24. ABUDOUBARI S, Tuersun A, Mutailipu S, Chen W, et al
    Interpretable machine learning models for bladder cancer overall survival prediction development and external validation via SEER database and Chinese cohort analysis.
    Discov Oncol. 2026 May 20. doi: 10.1007/s12672-026-05099.
    PubMed         Abstract available
    
    

    
    Discoveries (Craiova)

25. PAVALEAN MI, Madan VL, Pavalean MC, Ceafalan LC, et al
    The role of CD36 in renal and bladder cancer.
    Discoveries (Craiova). 2026;14:e225.
    PubMed         Abstract available
    
    

    
    Drug Dev Res

26. XIE X, Li Z, Qiu T, Li H, et al
    TRIM26-Mediated CBX6 Ubiquitination Triggers NETosis to Drive Bladder Cancer Tumor Growth via the CNPY2/NF-kappaB Signaling Pathway.
    Drug Dev Res. 2026;87:e70316.
    PubMed         Abstract available
    
    

    
    Eur Urol

27. HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
    Reply to Daoyuan Li's Words of Wisdom re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press.
    Eur Urol. 2026 May 21:S0302-2838(26)02159-7. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
28. MOSCHINI M, Scilipoti P, Longoni M, Montorsi F, et al
    Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269.
    Eur Urol. 2026 May 20:S0302-2838(26)02160-3. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
29. DI BELLO F, Gallioli A, Diana P, Avesani G, et al
    Re: Gallagher et al. RESECT, A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.09.4174.
    Eur Urol. 2026 May 20:S0302-2838(26)02163-9. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
30. COMPERAT E
    Re: Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
    Eur Urol. 2026 May 15:S0302-2838(26)01994-9. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
31. SUBIELA JD, Gonzalez-Padilla DA, Pichler R, Scilipoti P, et al
    Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient.
    Eur Urol. 2026 May 15:S0302-2838(26)02154-8. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Expert Rev Anticancer Ther

32. FAHEY C, Sud S, Remella A, Milowsky M, et al
    Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art.
    Expert Rev Anticancer Ther. 2026 May 15:1-16. doi: 10.1080/14737140.2026.2673109
    PubMed         Abstract available
    
    
33. DULF DV, Leo A, Coada CA
    Lymphovascular invasion in bladder cancer: from prognostic marker toward a clinical priority.
    Expert Rev Anticancer Ther. 2026 May 21. doi: 10.1080/14737140.2026.2679025.
    PubMed        
    
    

    
    Expert Rev Pharmacoecon Outcomes Res

34. LASALVIA P, Jaramillo P, Zapata M, Zapata M, et al
    Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.
    Expert Rev Pharmacoecon Outcomes Res. 2026;26:477-488.
    PubMed         Abstract available
    
    

    
    FASEB J

35. ZENG J, Cao Z, Wang C, Xu Y, et al
    Intravesical Delivery of P21 mRNA-Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer.
    FASEB J. 2026;40:e71904.
    PubMed         Abstract available
    
    

    
    Funct Integr Genomics

36. LIU K, Chen Z, Jin X, Liang H, et al
    An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.
    Funct Integr Genomics. 2026;26:103.
    PubMed         Abstract available
    
    

    
    Future Oncol

37. DE SANTIS M, Milloy N, Walley M, Simpson A, et al
    Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.
    Future Oncol. 2026;22:1429-1437.
    PubMed         Abstract available
    
    

    
    J Biotechnol

38. LIANG X, Sun Y, Guo Y, Liu B, et al
    Dual-Functional Chitosan-Hyaluronic Acid Dialdehyde Nanoparticles for CD44-Targeted Bcl-2 siRNA Delivery and Photothermal Therapy in Bladder Cancer.
    J Biotechnol. 2026 May 19:S0168-1656(26)00162.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

39. ZHANG X, Shen E, Cheng C, Meng R, et al
    Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report.
    J Cancer Res Clin Oncol. 2026 May 17. doi: 10.1007/s00432-026-06497.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

40. MURTHY V, Maitre P, Pal M, Arora A, et al
    Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2026 May 21:JCO2502093. doi: 10.1200/JCO-25-02093.
    PubMed         Abstract available
    
    

    
    J Formos Med Assoc

41. HSIEH CC, Tsai LJ, Lee HY, Juan YS, et al
    Arsenic exposure and trend of incidence in urinary cancer from 1979 to 2019: A nationwide population-based study.
    J Formos Med Assoc. 2026;125:507-515.
    PubMed         Abstract available
    
    

    
    J Immunother Cancer

42. DING Y, Jin K, Su X, Zhang L, et al
    Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.
    J Immunother Cancer. 2026;14:e014408.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

43. FLAIG TW, Spiess PE, Abern M, An Y, et al
    Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
    J Natl Compr Canc Netw. 2026;24:186-203.
    PubMed         Abstract available
    
    

    
    J Transl Med

44. FIGUERAS M, Ingelmo-Torres M, Roldan FL, Goma E, et al
    Role of Bladder EpiCheck((R)) in Bladder cancer: from primary diagnosis to surveillance.
    J Transl Med. 2026 May 18. doi: 10.1186/s12967-026-08249.
    PubMed         Abstract available
    
    

    
    J Urol

45. BAHLBURG H, Maas M, Contreras-Sanz A, Othman D, et al
    Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guerin.
    J Urol. 2026 May 20:101097JU0000000000005130. doi: 10.1097/JU.0000000000005130.
    PubMed         Abstract available
    
    
46. JOYCE DD, Sharma V, Ratcliff GE, Barocas DA, et al
    Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.
    J Urol. 2026 May 18:101097JU0000000000005126. doi: 10.1097/JU.0000000000005126.
    PubMed         Abstract available
    
    

    
    JCI Insight

47. XU W, Gao J, Wu S, Huang J, et al
    ELN orchestrates prometastatic and immunosuppressive niche in bladder cancer via TGFB1 autocrine signaling.
    JCI Insight. 2026;11:e194700.
    PubMed         Abstract available
    
    

    
    JMIR AI

48. LIU Y, Khetrapal P, Strafford R, Hadjivasilou A, et al
    Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.
    JMIR AI. 2026;5:e68994.
    PubMed         Abstract available
    
    

    
    Jpn J Radiol

49. SUGAWARA D, Mori N
    Comments on "Enhancing the performance of bp-MRI VI-RADS in detecting muscle-invasive bladder cancer".
    Jpn J Radiol. 2026 May 20. doi: 10.1007/s11604-026-02011.
    PubMed        
    
    

    
    Medicine (Baltimore)

50. CHEN J, Zuo J, Zhao J, Zhu X, et al
    From fat to tumor: Exploring the inflammatory bridge via CRP in obesity-related bladder cancer.
    Medicine (Baltimore). 2026;105:e48851.
    PubMed         Abstract available
    
    

    
    Mol Med

51. AKAND M, Nakauma-Gonzalez JA, Jatsenko T, Gevaert T, et al
    Transcriptomic profiling across stages of non-muscle-invasive bladder cancer identifies fibroblast activation protein-alpha as a stromal biomarker associated with progression.
    Mol Med. 2026 May 15. doi: 10.1186/s10020-026-01497.
    PubMed         Abstract available
    
    

    
    NPJ Precis Oncol

52. ZHENG Q, Mei H, Weng X, Yang R, et al
    Development and validation of artificial intelligence-based model for bladder cancer immunophenotyping using whole slide images.
    NPJ Precis Oncol. 2026 May 19. doi: 10.1038/s41698-026-01443.
    PubMed         Abstract available
    
    

    
    Nutr Cancer

53. LI S, Li G, Zhang X
    The Prognostic Nutritional Index Serves as a Novel and Independent Predictor of Recurrence in Patients with Non-Muscle-Invasive Bladder Cancer.
    Nutr Cancer. 2026 May 19:1-10. doi: 10.1080/01635581.2026.2674944.
    PubMed         Abstract available
    
    

    
    Occup Environ Med

54. ZIEMBICKI S, Kirkham TL, Arrandale VH, Navaneelan T, et al
    Cancer, chronic obstructive pulmonary disease and ischaemic heart disease in Ontario, Canada workers exposed to diesel engine exhaust.
    Occup Environ Med. 2026;83:78-84.
    PubMed         Abstract available
    
    

    
    Oncol Lett

55. LIU X, Bao Y
    Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer.
    Oncol Lett. 2026;32:288.
    PubMed         Abstract available
    
    

    
    Oncol Ther

56. SQUIRES P, Meng K, Hu X, Turzhitsky V, et al
    Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
    Oncol Ther. 2026 May 19. doi: 10.1007/s40487-026-00441.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

57. TANG F, Liao S, Hou X
    Infection-driven bladder carcinogenesis: Molecular mechanisms of pathogen-urothelial cell interactions.
    Pathol Res Pract. 2026;283:156488.
    PubMed         Abstract available
    
    
58. ZHANG D, Li X, Xu X, Su M, et al
    METTL3 promotes the progression of bladder cancer through the METTL3/IGF2BP3/MTA1/PI3K/AKT axis.
    Pathol Res Pract. 2026;284:156489.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

59. ZHAN W, An D, Lei J, Un H, et al
    Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer patients.
    Transl Androl Urol. 2026;15:110.
    PubMed         Abstract available
    
    
60. DELRUE C, Oyaert M, Speeckaert MM
    Urinary PENK DNA methylation for bladder cancer diagnosis: methodological rigor, interpretive boundaries, and the evidence required for clinical translation.
    Transl Androl Urol. 2026;15:97.
    PubMed        
    
    
61. BRYAN RT, Goel A, Ward DG
    PENK methylation and non-invasive bladder cancer detection.
    Transl Androl Urol. 2026;15:96.
    PubMed        
    
    
62. CAI S, Ren X, Xia D, Wang M, et al
    MDM4 promotes chemoresistance in bladder cancer by attenuating P53-mediated EMT.
    Transl Androl Urol. 2026;15:112.
    PubMed         Abstract available
    
    
63. ZHOU X, Weng L, Sun T, Jiang Q, et al
    Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer.
    Transl Androl Urol. 2026;15:132.
    PubMed         Abstract available
    
    
64. XIA Y, Ma B, Huang T, Liu X, et al
    Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study.
    Transl Androl Urol. 2026;15:119.
    PubMed         Abstract available
    
    
65. DUQUESNE I, Chakra MA, Myers AA, Boormans JL, et al
    Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay.
    Transl Androl Urol. 2026;15:94.
    PubMed        
    
    
66. YUAN J, Xing S, Sun W, Zeng S, et al
    Knowledge mapping of photodynamic therapy in bladder cancer: a bibliometric analysis (2000-2025).
    Transl Androl Urol. 2026;15:133.
    PubMed         Abstract available
    
    
67. LIU Z, Tan T, Li S, Wang Y, et al
    Bioinformatics analysis and experimental approach identify BRD-family gene DSP as a diagnostic and prognostic indicator in bladder cancer.
    Transl Androl Urol. 2026;15:124.
    PubMed         Abstract available
    
    

    
    Urol Oncol

68. ANGULO-LOZANO JC, Posada-Calderon L, Liu H, Blanchard L, et al
    Effective PD-1 checkpoint blockade in bladder cancer model requires tumor-draining lymph nodes and lymphocyte trafficking.
    Urol Oncol. 2026 May 21:S1078-1439(26)00501.
    PubMed         Abstract available
    
    

    
    World J Surg Oncol

69. CHEN R, Wu D, Wu W, Yang J, et al
    H3K18 lactylation promotes glycolysis in bladder cancer via inhibiting GNG7 through regulating PI3K-AKT signaling pathway.
    World J Surg Oncol. 2026 May 21. doi: 10.1186/s12957-026-04405.
    PubMed         Abstract available
    
    
70. WANG Y, Nai Z, Zhang J
    LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1.
    World J Surg Oncol. 2026 May 18. doi: 10.1186/s12957-026-04391.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum